CELENEX
CELENEX
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Columbus, Ohio, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
0
Similar Organizations
Antoxis
Antoxis is developing treatments for various neurological conditions.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
EspeRare
Advancing treatments for rare diseases Together
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Investors List
Rev1 Ventures
Rev1 Ventures investment in Seed Round - Celenex
More informations about "Celenex"
Celenex 2025 Company Profile: Valuation, Investors, Acquisition
Celenex General Information Description. Developer of gene therapy programs. The company's therapies use a similar approach to the SMA gene therapy. A modified adeno-associated …See details»
Celenex - Crunchbase Company Profile & Funding
Celenex is located in Columbus, Ohio, United States. Who invested in Celenex? Celenex is funded by Rev1 Ventures. When was the last funding round for Celenex? Celenex closed its …See details»
Amicus Therapeutics to buy Celenex for $100m upfront
US-based biotechnology firm Amicus Therapeutics has entered into a definitive agreement to buy clinical stage gene therapy firm Celenex for $100m in an upfront payment. The transaction will …See details»
Amicus Therapeutics Buys Celenex for $100 Million up Front
Sep 20, 2018 Celenex was a spinout of Nationwide Children’s Hospital. Under the terms of the deal, Amicus will pay $100 million up front in cash. Celenex shareholders are eligible for up to …See details»
Celenex Acquired by Amicus Therapeutics for $100MM+
Sep 21, 2018 It is our pleasure to share with you that Rev1 portfolio company, Celenex, has been acquired by Amicus Therapeutics. Celenex licensed technology from Nationwide …See details»
Amicus Expands into Gene Therapy with Celenex Acquisition
Sep 20, 2018 Celenex shareholders are also eligible for up to $75 million in payments tied to tiered sales milestones (tiers of $500 million/$750 million). The acquisition and several years …See details»
Amicus joins gene therapy surge with $100M pipeline …
Sep 20, 2018 Amicus Therapeutics has paid $100 million to buy Celenex. The takeover gives Amicus a ready-made pipeline of 10 gene therapies, including two that are in clinical trials. New Jersey’s Amicus has ...See details»
Amicus Therapeutics to Acquire Celenex, Scoring Gene Therapy …
Sep 20, 2018 Amicus Therapeutics agreed to acquire Celenex in a deal that provides it worldwide development and commercial rights for ten gene therapy programs for $100 million …See details»
Fenwick Represents Celenex in Acquisition by Amicus
Oct 4, 2018 Fenwick & West represented Celenex, a private, clinical stage gene therapy company, in its acquisition by Amicus Therapeutics (Nasdaq: FOLD), a global, patient-centric …See details»
Amicus buys gene therapy firm Celenex - Chemical & Engineering …
Sep 21, 2018 Rare disease-focused Amicus Therapeutics is shelling out $100 million up front, and up to $350 million more in milestones, for the privately held gene therapy developer Celenex.See details»
Amicus Therapeutics acquires gene therapy portfolio with Celenex …
Sep 21, 2018 New Jersey, USA-based rare diseases drugmaker Amicus Therapeutics(Nasdaq: FOLD) has dived into the gene therapy sector, agreeing to paying an upfront of $100 million …See details»
Celenex - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Mar 1, 2018: Seed Round - …See details»
Amicus Expands into Gene Therapy with Celenex Acquisition
Sep 20, 2018 Celenex shareholders are also eligible for up to $75 million in payments tied to tiered sales milestones (tiers of $500 million/$750 million). The acquisition and several years …See details»
Celenex | Anthem Venture Partners
Acquired by: Amicus Therapeutics Celenex delivers a life-saving gene therapy treatment that cures children with Batten disease, a group of severe neurodegenerative disorders …See details»
Startup acquired in $100M deal - Ohio State University
Celenex is based on research by Ohio State professor Arthur Burghes and two colleagues at Nationwide Children’s hospital, Drs. Brian Kaspar and Kathrin Meyer. Through Ohio State’s …See details»
Amicus, Thermo Fisher's Brammer Bio Partner on Gene Therapy Manufacturing
Last month during the 2019 Biotechnology Innovation Organization (BIO) International ... The acquisition of Celenex and Nationwide/Ohio gene therapy programs was one of two …See details»
Amicus secures new gene therapy portfolio with Celenex buy for …
Sep 21, 2018 Rare disease specialist Amicus Therapeutics Inc. is breaking into the gene therapy field with the acquisition of 10 new assets through its purchase of Ohio-based Celenex …See details»
Celenex - Products, Competitors, Financials, Employees, …
Celenex had several research programs that originated within Nationwide Children's Hospital, one of the nation's top gene therapy hubs. Amicus has since bought several others from the …See details»
Celenex, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Celenex, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Celenex - Rev1 Ventures
Celenex Acquired by Amicus Therapeutics for $100MM+ By Tom Walker on 09/21/2018. Celenex in the News. Nationwide Children’s gene therapy spinoff acquired for $100M. Company News . …See details»